Eli Lilly has seen revenue and earnings soar in recent years.

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...

Richard Saperstein, Chief Investment Officer at Treasury Partner, joins CNBC's Halftime Report to detail his latest portfolio ...

Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a ...

Sanofi is leading commercialization efforts for Nuvaxovid and Novavax is eligible to receive ongoing tiered royalties from sales of the vaccine. A full 12-month commercial cycle under Sanofi’s control ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.

Democrats sue the Trump administration over the CDC's recent changes to the U.S. childhood vaccine schedule. Read more here.

Pfizer's obesity-related pipeline is gaining substantial momentum. On February 3, 2026, the company announced positive Phase 2b results from its VESPER-3 study for PF-08653944, a long-acting ...

Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...

Vaxcyte Inc (PCVX) reports promising clinical trial outcomes and financial strength, while navigating competitive challenges and future expenses.

If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the numbers actually say about the stock. Pfizer's recent share price reflects ...